The United States Food and Drug Administration (US FDA) has approved the first fixed-dose combination (FDC) tablet containing Acetaminophen (also known as Paracetamol) and Naproxen sodium for over-the-counter (OTC) use. The approval was granted on 24 July 2026, marking a significant milestone in the field of nonprescription pain management. The newly approved formulation contains 325 mg of Acetaminophen and 110 mg of Naproxen sodium per tablet. The New Drug Application (NDA No. 219962) was submitted by Kenvue Brands LLC, and the product received approval under the 505(b)(2) regulatory pathway, which allows sponsors to rely partly on existing scientific evidence while providing additional data demonstrating the safety and effectiveness of the new product.
The product has also been granted 3 years of marketing exclusivity by US FDA, highlighting the novelty of the formulation as the first approved OTC fixed-dose combination of these two widely used analgesics. The exclusivity period will provide the sponsor with a competitive advantage while encouraging pharmaceutical innovation in the nonprescription medicines market. Following the approval, the product is expected to become available through retail pharmacies and other OTC distribution channels across the United States in the near future.
According to the approved labelling, the recommended dosage for adults and children aged 12 years and older is 2 tablets every 12 hours, providing prolonged pain relief with a convenient twice-daily dosing regimen. The combination has been indicated for the temporary relief of minor aches and pains, including headache, backache, muscular aches, toothache, menstrual cramps, minor pain associated with arthritis, and other common painful conditions. The formulation has been designed to provide up to 12 hours of pain relief following a single dose, thereby reducing the need for frequent dosing throughout the day.
Although the detailed clinical data supporting the approval have not yet been published in any peer-reviewed scientific journal, the company has announced that the findings from the clinical development program will be presented during PainWeek 2026, scheduled to be held in Las Vegas in September 2026. The forthcoming presentation is expected to provide clinicians, researchers, and regulatory professionals with greater insight into the pharmacological rationale, efficacy outcomes, and safety profile of the combination product.
Acetaminophen and Naproxen sodium are among the most frequently used OTC analgesics worldwide, each possessing decades of clinical experience and well-established safety profiles when used according to labelled recommendations. Acetaminophen is primarily recognized for its analgesic and antipyretic properties, while Naproxen sodium belongs to the class of nonsteroidal anti-inflammatory drugs (NSAID), offering analgesic, anti-inflammatory, and antipyretic effects. The practice of using both medications together for enhanced pain relief is not new. Healthcare professionals have often recommended their concurrent administration for selected painful conditions because they act through different pharmacological mechanisms, thereby potentially producing complementary analgesic effects.
However, until now, patients wishing to use both medications simultaneously were required to purchase two separate products and follow individualized dosing schedules. The newly approved product eliminates this inconvenience by providing both active ingredients in a single fixed-dose tablet, thereby simplifying medication use, improving dosing convenience, and potentially enhancing patient adherence. Importantly, this represents the first US FDA-approved OTC FDC of Acetaminophen and Naproxen sodium, distinguishing it from previous prescription or non-fixed combination approaches.
Acetaminophen has previously been approved in combination with several other active pharma ingredients. These include Codeine phosphate, Hydrocodone bitartrate, Ibuprofen, Pentazocine hydrochloride, Aspirin plus Caffeine, Aspirin plus Codeine phosphate, Caffeine plus Dihydrocodeine bitartrate, and Oxycodone hydrochloride. Many of these combinations are prescription-only products, particularly those containing opioid analgesics. Consequently, the newly approved Acetaminophen-Naproxen sodium combination represents a unique addition to the OTC analgesic market by offering a non-opioid combination therapy that provides prolonged pain relief without the risks associated with opioid-containing medications.
The development program for the product was specifically designed to answer an important clinical question: Can a single, opioid-free OTC FDC provide both rapid onset and sustained pain relief without requiring patients to combine multiple medications on their own? To address this question, the sponsor conducted an extensive clinical development program consisting of eight clinical studies. According to the company, the studies demonstrated several important clinical benefits, including:
- Superior pain relief compared with Acetaminophen alone.
- Superior pain relief compared with Naproxen sodium alone.
- Onset of meaningful pain relief in less than 30 minutes.
- Sustained analgesic effect lasting up to 12 hours following a single dose.
The approved labelling incorporates the standard warnings and precautions associated with both active ingredients. Similar to other Acetaminophen-containing products, the labelling clearly warns consumers not to use the combination simultaneously with other medicines containing Acetaminophen, as doing so may increase the risk of serious liver injury or hepatotoxicity resulting from inadvertent overdose. Consumers are advised to carefully review the active ingredients of all medications they are taking before initiating therapy with the new product.
The labelling also includes the well-established warnings associated with Naproxen sodium. Patients with a history of gastrointestinal ulceration or bleeding, cardiovascular disease, kidney impairment, or hypersensitivity to NSAID should exercise caution and consult healthcare professionals before using the product. In addition, the Drug Facts label advises that pregnant or breastfeeding women should consult a healthcare professional before use. Consistent with current US FDA recommendations regarding NSAID use during pregnancy, the label specifically states that Naproxen sodium should not be used at 20 weeks of pregnancy or later unless specifically directed by a physician, owing to the potential risk of fetal kidney dysfunction and reduced amniotic fluid.
The US FDA has stated that the approval is consistent with President Donald Trump's "The Great Healthcare Plan," an initiative intended to expand access to safe and effective medicines through the OTC market whenever appropriate. The broader objectives of the initiative include improving public access to healthcare, reducing prescription drug costs, lowering insurance premiums, increasing transparency in healthcare pricing, and encouraging the availability of scientifically evaluated medicines without requiring a prescription when supported by adequate evidence of safety and efficacy.
The FDC of Paracetamol and Naproxen was banned in India in 2016 for manufacturing and sale, quoting no therapeutic justification, although the strengths of the APIs were different compared to the recently approved US FDA’s product. The regulatory environments governing FDC approvals differ substantially between jurisdictions. India has historically witnessed the marketing of numerous FDCs without adequate scientific evidence supporting their safety, efficacy, or therapeutic rationale. Consequently, India has undertaken several regulatory initiatives to eliminate irrational FDCs from the market. In a recent regulatory action, on 20 June 2026, following directions issued by the Supreme Court of India, the Govt prohibited the manufacture, sale, and distribution of 16 irrational FDCs, including three products containing Paracetamol. Earlier, on 2 August 2024, the Govt had similarly banned 156 FDCs, of which 16 formulations contained Paracetamol. These regulatory actions demonstrate India's continuing commitment to ensuring that marketed FDCs are supported by adequate scientific evidence, therapeutic justification, and an acceptable benefit-risk profile. Many of the prohibited formulations belonged to commonly used therapeutic categories such as antibiotics, analgesics, cough and cold preparations, and dermatological products.
The contrast between these regulatory developments in India and the recent US FDA approval underscores an important principle in pharmaceutical regulation: the acceptability of an FDC depends not merely on the individual safety profiles of its constituent drugs but on the availability of robust scientific evidence demonstrating that the combination itself provides meaningful therapeutic benefits without introducing unnecessary risks. Regulatory authorities worldwide increasingly emphasize evidence-based decision-making, requiring sponsors to justify the pharmacological rationale, clinical efficacy, dosing convenience, and safety of every new combination product.
It is also worth noting the terminology used for one of the active ingredients. The name "Acetaminophen" is predominantly used in the US and Japan, whereas the term "Paracetamol" is commonly used in most other parts of the world, including Europe, Australia, India, New Zealand, and many Asian and African countries. Both names refer to the same active pharma ingredient, and the difference is purely nomenclatural rather than pharmacological.
Overall, the US FDA approval of the first OTC FDC of Acetaminophen and Naproxen sodium represents a significant advancement in nonprescription pain management. The formulation combines two well-established analgesics with complementary mechanisms of action into a single convenient dosage form, offering rapid onset of analgesia together with prolonged pain relief while avoiding opioid exposure. As additional clinical evidence becomes publicly available and post-marketing experience accumulates, the product will provide valuable insights into the role of scientifically justified FDCs in improving patient convenience, treatment adherence, and pain management outcomes.
(The author is a New Delhi based academician and R&D consultant) |